What's new? Log in Free sign up

Altimmune (ALT)

Company Profile

Company profile

Ticker

ALT

Exchange

Website

CEO

Dr. Vipin K. Garg Ph.D.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris • AbbVie • Bausch Health Companies ...

Former names

HEALTHCARE ACQUISITION CORP, PHARMATHENE, INC

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Altimmune, LLC • Altimmune UK, Limited • Spitfire Pharma, LLC • Altimmune AU Pty, Limited ...

IRS number

202726770

ALT stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

Shelf registration

Registration of securities for employees

27 Feb 25

Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors

Quarterly report

12 Nov 24

Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update

Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer

Submission of Matters to a Vote of Security Holders

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Jerome Benedict Durso

Jerome Benedict Durso

AMERIPRISE FINANCIAL INC

Catherine A. Sohn

BlackRock, Inc.

Matthew Scott Harris

Raymond M Jordt

Financial summary

Financial statements Chart ALT financial data

Quarter (USD)	Dec 24	Sep 24	Jun 24	Mar 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	36.97 mm	36.97 mm	36.97 mm	36.97 mm	36.97 mm	36.97 mm
Cash burn (monthly)	(no burn)	8.18 mm	8.29 mm	8.60 mm	6.09 mm	6.65 mm
Cash used (since last report)	n/a	17.02 mm	17.24 mm	17.89 mm	12.67 mm	13.84 mm
Cash remaining	n/a	19.94 mm	19.72 mm	19.08 mm	24.30 mm	23.12 mm
Runway (months of cash)	n/a	2.4	2.4	2.2	4.0	3.5

Beta Read what these cash burn values mean

Financial data from Altimmune earnings reports.

Institutional ownership, Q4 2024

ALT institutional ownership history Ownership history

73.5% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	192	179	+7.3%
Opened positions	40	23	+73.9%
Closed positions	27	29	-6.9%
Increased positions	63	59	+6.8%
Reduced positions	43	45	-4.4%

13F shares	Current	Prev Q	Change
Total value	285.41 bn	236.35 bn	+20.8%
Total shares	52.28 mm	51.36 mm	+1.8%
Total puts	1.38 mm	743.20 k	+85.5%
Total calls	1.93 mm	910.90 k	+112.2%
Total put/call ratio	0.7	0.8	-12.6%

Largest owners	Shares	Value	Change
BlackRock	6.16 mm	$44.41 bn	+12.7%
AMP Ameriprise Financial	5.25 mm	$37.89 bn	+35.6%
Vanguard	4.43 mm	$31.95 bn	-11.1%
STT State Street	3.47 mm	$25.02 bn	+1.6%
Tang Capital Partners	2.75 mm	$26.95 mm	0.0%
Tang Capital Management	2.75 mm	$19.83 bn	0.0%
Velocity Pharmaceutical	1.94 mm	$21.86 mm	0.0%
Venrock Healthcare Capital Partners II	1.76 mm	$16.13 mm	0.0%
Geode Capital Management	1.66 mm	$11.96 bn	-0.6%
Tiaa Cref Investment Management	1.55 mm	$15.18 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
AMP Ameriprise Financial	5.25 mm	+1.38 mm	+35.6%
Capital Fund Management	0.00	-726.83 k	EXIT
BlackRock	6.16 mm	+693.21 k	+12.7%
Vanguard	4.43 mm	-552.25 k	-11.1%
UBS UBS	719.56 k	+437.10 k	+154.8%
Susquehanna International	500.92 k	-426.04 k	-46.0%
GS The Goldman Sachs Group, Inc.	526.17 k	-406.66 k	-43.6%
MS Morgan Stanley	921.82 k	-373.76 k	-28.8%
D. E. Shaw & Co.	459.83 k	-298.17 k	-39.3%
Gsa Capital Partners	82.96 k	-256.64 k	-75.6%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ALT insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
24 Feb 25	Durso Jerome Benedict	Stock Options (option to buy) Common Stock, par value $0.0001	Grant	Acquire A	No	No	6.11	69,800	426.48 k	69,800
24 Feb 25	Teri L Lawver	Stock Options (option to buy) Common Stock, par value $0.0001	Grant	Acquire A	No	No	6.11	69,800	426.48 k	69,800
6 Feb 25	Sohn Catherine A.	Stock Options (option to buy) Common Stock, par value $0.0001	Grant	Acquire A	No	No	6.91	18,600	128.53 k	18,600

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

William Blair Initiates Coverage On Altimmune with Market Perform Rating

William Blair analyst Andy Hsieh initiates coverage on Altimmune (NASDAQ:ALT) with a Market Perform rating.

Altimmune Q4 2024 GAAP EPS $(0.33), Inline, Sales $5.00K Down From $37.00K YoY, Cash, Cash Equivalents And Short-term Investments Of $131.9M

Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.33) per share which met the analyst consensus estimate. This is a 38.89 percent increase over losses of $(0.54) per share from the same period last year. The

Earnings Scheduled For February 27, 2025

HC Wainwright & Co. Reiterates Buy on Altimmune, Maintains $12 Price Target

Press releases

From Benzinga Pro

Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors

Ms. Lawver, former Chief Commercial Officer of Dexcom and Global Vice President at Johnson & Johnson responsible for billion-dollar Immunology and Cardiovascular & Metabolism Portfolios over her 20-year career

Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025

GAITHERSBURG, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2024 financial results

Sprout Social, Altimmune, Equinix, and Globe Life Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

SAN DIEGO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is conducting a thorough investigation into possible violations of securities laws by specific officers at Sprout Social, Inc. (NASDAQ:SPT), Altimmune,

Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference

Altimmune Added to Nasdaq Biotechnology Index

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.